General

Title
Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counseled regarding psychosocial AND pharmacologic treatment options for opioid addiction within the 12 month reporting period.

Source(s)

Measure Domain

Primary Measure Domain
Process
The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the Measure Validity page.

Secondary Measure Domain
Does not apply to this measure

Brief Abstract

Description
This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counseled regarding psychosocial and pharmacologic treatment options for opioid addiction within the 12 month reporting period.

Rationale
Methadone and buprenorphine, in combination with psychosocial treatment, are effective in reducing drug use and supporting treatment retention. Until recently, their use had been limited due to regulatory requirements with capacity at approved facilities only able to meet the treatment needs of 15% of opioid dependent individuals. While the increased access to opioid agonist treatments has resulted in an increase in their use, a large number of clinicians have yet to gain eligibility to prescribe the appropriate medications. Moreover, among physicians with waivers to prescribe buprenorphine, 33% were not actively prescribing. Pharmacotherapy and psychosocial treatment should be routinely considered for all patients
with opioid addiction, and patients should be informed of this option. * 

The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure:

Empirically validated psychosocial treatment interventions should be initiated for all patients with substance use illnesses. (National Quality Forum [NQF])

Pharmacotherapy should be recommended and available to all adult patients diagnosed with opioid dependence and without medical contraindications. Pharmacotherapy, if prescribed, should be provided in addition to and directly linked with psychosocial treatment/support. (NQF)

Maintenance treatment with methadone or buprenorphine is appropriate for patients with a prolonged history (greater than 1 year) of opioid dependence. (American Psychiatric Association [APA])

Maintenance treatment with naltrexone is an alternative strategy, although the utility of this strategy is often limited by lack of patient adherence and low treatment retention. (APA)

Psychosocial treatments are effective components of a comprehensive treatment plan for patients with an opioid use disorder. Behavioral therapies (e.g., contingency management), cognitive behavioral therapies (CBTs), psychodynamic psychotherapy, and group and family therapies have been found to be effective for some patients with an opioid use disorder. (APA)

Note: Federal and state regulations govern the use of methadone, levo-alpha-acetylmethadol (LAAM), and buprenorphine, the three opioids approved by the FDA for the treatment of opioid dependence. (APA) 
[Note: since the publication of the APA practice guideline, LAAM is no longer available in the United States for agonist maintenance treatment.]

The American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine issued a consensus statement to recognize and recommend definitions related to the use of opioids for the treatment of pain. They are as follows:

Addiction: Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving.

Physical Dependence: Physical dependence is a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.

Tolerance: Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug’s effects over time.

Addiction in the context of pain treatment with opioids is characterized by a persistent pattern of opioid misuse that may involve any or all of the following:

- Use of prescription opioids in an unapproved or inappropriate manner (such as cutting time-release preparations, injecting oral formulations, and applying fentanyl topical patches to oral or rectal mucosa)
- Obtaining opioids outside of medical settings
- Concurrent abuse of alcohol or illicit drugs
- Repeated requests for dose increases or early refills, despite the presence of adequate analgesia
- Multiple episodes of prescription "loss"
- Repeatedly seeking prescriptions from other clinicians or from emergency rooms without informing prescriber, or after warnings to desist
- Evidence of deterioration in the ability to function at work, in the family, or socially, which appears to be related to drug use
- Repeated resistance to changes in therapy despite clear evidence of adverse physical or psychological effects from the drug
- Positive urine drug screen* for other substance use (cocaine, opioids, amphetamines or alcohol)
- Meets DSM IV criteria for dependence on opioids (VA/DoD)

Primary Clinical Component

Opioid addiction; counseling; psychosocial and pharmacologic treatment

Denominator Description

All patients aged 18 years and older with a diagnosis of current opioid addiction (see the related "Denominator Inclusions/Exclusions" field)

Numerator Description

Patients who were counseled regarding psychosocial AND pharmacologic treatment options for opioid addiction within the 12 month reporting period

Evidence Supporting the Measure

Evidence Supporting the Criterion of Quality
A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

Evidence Supporting Need for the Measure

Need for the Measure
Use of this measure to improve performance

Evidence Supporting Need for the Measure


State of Use of the Measure

State of Use
Current routine use

Current Use
Internal quality improvement

Application of Measure in its Current Use

Care Setting
Ambulatory Care
Behavioral Health Care
Physician Group Practices/Clinics
Substance Use Treatment Programs/Centers

Professionals Responsible for Health Care
Physicians
Psychologists/Non-physician Behavioral Health Clinicians

Lowest Level of Health Care Delivery Addressed
Individual Clinicians
Target Population Age
Age greater than or equal to 18 years

Target Population Gender
Either male or female

Stratification by Vulnerable Populations
Unspecified

Characteristics of the Primary Clinical Component

Incidence/Prevalence
Unspecified

Association with Vulnerable Populations
Unspecified

Burden of Illness
Unspecified

Utilization
Unspecified

Costs
Unspecified

Institute of Medicine (IOM) Healthcare Quality Report Categories

IOM Care Need
Getting Better

IOM Domain
Effectiveness
Patient-centeredness
Data Collection for the Measure

Case Finding

Users of care only

Description of Case Finding

All patients aged 18 years and older with a diagnosis of current opioid addiction

Denominator Sampling Frame

Patients associated with provider

Denominator Inclusions/Exclusions

Inclusions

All patients aged 18 years and older with a diagnosis of current opioid addiction

*The term “opioid addiction” in this context corresponds to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) classification of opioid dependence that is characterized by a maladaptive pattern of substance use causing clinically significant impairment or distress, and manifesting by 3 (or more) of the 7 designated criteria. This classification is distinct from and not to be confused with physical dependence (i.e., tolerance and withdrawal) that is commonly experienced by patients with chronic pain who are treated with opioid analgesics. Refer to the “Rationale” field for additional information regarding this distinction.

Exclusions

Patients may be excluded from the denominator for medical, patient or system reasons. Refer to the original measure documentation for details.

Relationship of Denominator to Numerator

All cases in the denominator are equally eligible to appear in the numerator

Denominator (Index) Event

Clinical Condition

Encounter

Denominator Time Window

Time window is a single point in time

Numerator Inclusions/Exclusions

Inclusions

Patients who were counseled regarding psychosocial AND pharmacologic treatment options for opioid addiction within the 12 month reporting period

Exclusions

None
Measure Results Under Control of Health Care Professionals, Organizations and/or Policymakers

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

Numerator Time Window

Fixed time period

Data Source

Administrative data
Medical record

Level of Determination of Quality

Individual Case

Pre-existing Instrument Used

Unspecified

Computation of the Measure

Scoring

Rate

Interpretation of Score

Better quality is associated with a higher score

Allowance for Patient Factors

Unspecified

Standard of Comparison

Internal time comparison

Evaluation of Measure Properties

Extent of Measure Testing

Unspecified
Identifying Information

Original Title
Measure #2: counseling regarding psychosocial and pharmacologic treatment options for opioid addiction.

Measure Collection Name
The Physician Consortium for Performance Improvement® Measurement Sets

Measure Set Name
Substance Use Disorders Physician Performance Measurement Set

Submitter
American Medical Association on behalf of the American Psychiatric Association, Physician Consortium for Performance Improvement®, and National Committee for Quality Assurance - Medical Specialty Society

Developer
American Psychiatric Association - Medical Specialty Society
National Committee for Quality Assurance - Health Care Accreditation Organization
Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration

Funding Source(s)
Unspecified

Composition of the Group that Developed the Measure
Daniel Kivlahan, PhD (Co-Chair); Mark L. Willenbring, MD (Co-Chair); James G. Adams, MD; Joann Albright, PhD; Charles E. Argoiff, MD; Ray M. Baker, MD; Richard L. Brown, MD, MPH; Audrey Burnam, PhD; Mirean Coleman, MSW, LICSW, CT; Edward C. Covington, MD; Thomas J. Craig, MD, MPH; Ann Doucette, PhD; Larry M. Gentilello, MD; Eric Goplerud, PhD, MA; Constance Horgan, ScD; Herbert D. Kleber, MD; Petros Levounis, MD; Bertha K. Madras, PhD; Frank McCorry, PhD; Ann H. Messer, MD; Michael M. Miller, MD, FASAM, FAPA; Doug Nemecek, MD, MBA; Harold Alan Pincus, MD; Rhonda Robinson-Beale, MD; Richard N. Rosenthal, MD; Darlene Warrick McLaughlin, MD; Scott C. Williams, PsyD
Beatrice Eld, American Psychiatric Association; Robert Plovnick, MD, MS, American Psychiatric Association
Joseph Gave, MPH, American Medical Association; Karen Kmetik, PhD, American Medical Association; Shannon Sims, MD, PhD, American Medical Association; Samantha Tierney, MPH, American Medical Association; Richard Yoast, PhD, American Medical Association
Lisa Nern, MSW, National Committee for Quality Assurance; Philip Renner, MBA, National Committee for Quality Assurance
Sylvia Publ, MBA, RHIA, Centers for Medicare & Medicaid Service
Rebecca Kresowiak, PCPI Consultant; Timothy Kresowiak, MD PCPI Consultant
Financial Disclosures/Other Potential Conflicts of Interest

Conflicts, if any, are disclosed in accordance with the Physician Consortium for Performance Improvement® conflict of interest policy.

Included in

Ambulatory Care Quality Alliance

Adaptation

Measure was not adapted from another source.

Release Date

2008 Jul

Measure Status

This is the current release of the measure.

The Physician Consortium for Performance Improvement reaffirmed the currency of this measure in November 2010.

Source(s)


Measure Availability

The individual measure, "Measure #2: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Opioid Addiction," is published in the "Substance Use Disorders Physician Performance Measurement Set." This document and technical specifications are available in Portable Document Format (PDF) from the American Medical Association (AMA)-convened Physician Consortium for Performance Improvement® Web site: www.physicianconsortium.org.

For further information, please contact AMA staff by e-mail at cqi@ama-assn.org.

NQMC Status

This NQMC summary was completed by ECRI Institute on November 3, 2008. The information was verified by the measure developer on December 4, 2008. The information was reaffirmed by the measure developer on November 17, 2010.

Copyright Statement

© 2008 American Medical Association and National Committee for Quality Assurance. All Rights Reserved. CPT® Copyright 2007 American Medical Association.

Disclaimer
NQMC Disclaimer

The National Quality Measures Clearinghouseâ“¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.